{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T08:09:33Z","timestamp":1774166973180,"version":"3.50.1"},"reference-count":83,"publisher":"Bentham Science Publishers Ltd.","issue":"10","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2019,7,12]]},"abstract":"<jats:sec><jats:title\/><jats:p>Naltrexone is a competitive opioid receptor antagonist approved as supportive treatment in alcohol dependence and opioid addiction. At a dose of 50-100 mg daily, naltrexone is used off-label in dermatology for the treatment of trichotillomania and different types of pruritus. At a dose as low as 1- 5 mg per day, naltrexone demonstrates immunomodulatory action i.e. modulates Toll-like receptors signaling, decreases release of proinflammatory cytokines (tumor necrosis factor, interleukin-6, interleukin- 12), inhibits T lymphocyte proliferation, down-regulates the expression of chemokine receptors and adhesion molecules. The efficacy of standard and low doses of naltrexone in a variety of dermatological disorders has been reported. These include diseases such as familial benign chronic pemphigus (Hailey-Hailey disease), dermatomyositis, systemic sclerosis, psoriasis and lichen planopilaris. Optimistic preliminary findings, low cost of therapy and good tolerance make naltrexone a promising alternative therapy or adjunct drug in dermatology.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1389450120666190318121122","type":"journal-article","created":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T09:34:42Z","timestamp":1552988082000},"page":"1058-1067","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The Use of Naltrexone in Dermatology. Current Evidence and Future Directions"],"prefix":"10.2174","volume":"20","author":[{"given":"Mariusz","family":"Sikora","sequence":"first","affiliation":[{"name":"Department of Dermatology, Medical University of Warsaw, Koszykowa 82A, 02-008 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Rakowska","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical University of Warsaw, Koszykowa 82A, 02-008 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata","family":"Olszewska","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical University of Warsaw, Koszykowa 82A, 02-008 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidia","family":"Rudnicka","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical University of Warsaw, Koszykowa 82A, 02-008 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s13181-015-0512-x","volume":"12","author":"Sudakin D.","year":"2016","unstructured":"Sudakin D. Naltrexone: Not just for opioids anymore.","journal-title":"J Med Toxicol"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/ajad.12711","volume":"27","author":"Bisaga A.","year":"2018","unstructured":"Bisaga A, Mannelli P, Sullivan MA. Antagonists in the medical management of opioid use disorders: Historical and existing treatment strategies.","journal-title":"Am J Addict"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/apt.13965","volume":"45","author":"Goh E.T.","year":"2017","unstructured":"Goh ET, Morgan MY. Review article: Pharmacotherapy for alcohol dependence - the why, the what and the wherefore.","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.beem.2018.06.007","volume":"32","author":"Grandone A.","year":"2018","unstructured":"Grandone A, Di Sessa A, Umano GR, Toraldo R, Miraglia Del Giudice E. New treatment modalities for obesity.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.drugalcdep.2018.06.038","volume":"191","author":"Lee N.K.","year":"2018","unstructured":"Lee NK, Jenner L, Harney A, Cameron J. Pharmacotherapy for amphetamine dependence: A systematic review.","journal-title":"Drug Alcohol Depend"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3109\/10550490903077929","volume":"18","author":"Schmitz J.M.","year":"2009","unstructured":"Schmitz JM, Lindsay JA, Green CE, Herin DV, Stotts AL, Moeller FG. High-dose naltrexone therapy for cocaine-alcohol dependence.","journal-title":"Am J Addict"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000480539","volume":"23","author":"Mouaffak F.","year":"2017","unstructured":"Mouaffak F, Leite C, Hamzaoui S. Naltrexone in the treatment of broadly defined behavioral addictions: A review and meta-analysis of randomized controlled trials.","journal-title":"Eur Addict Res"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1007\/s12325-017-0613-9","volume":"34","author":"Guerdjikova A.I.","year":"2017","unstructured":"Guerdjikova AI, Walsh B, Shan K. Concurrent improvement in both binge eating and depressive symptoms with Naltrexone\/ Bupropion therapy in overweight or obese subjects with major depressive disorder in an open-label, uncontrolled study.","journal-title":"Adv Ther"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/jir.12122","volume":"59","author":"Roy A.","year":"2015","unstructured":"Roy A, Roy M, Deb S, Unwin G, Roy A. Are opioid antagonists effective in attenuating the core symptoms of autism spectrum conditions in children: a systematic review.","journal-title":"J Intellect Disabil Res"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1007\/s00105-004-0802-8","volume":"55","author":"Brune A.","year":"2004","unstructured":"Brune A, Metze D, Luger TA, Stander S. Antipruritic therapy with the oral opioid receptor antagonist naltrexone. Open, non-placebo controlled administration in 133 patients.","journal-title":"Hautarzt"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s40263-016-0373-0","volume":"30","author":"Aboujaoude E.","year":"2016","unstructured":"Aboujaoude E, Salame WO. Naltrexone: A pan-addiction treatment?","journal-title":"CNS Drugs"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.intimp.2018.05.020","volume":"61","author":"Li Z.","year":"2018","unstructured":"Li Z, You Y, Griffin N, Feng J, Shan F. Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy.","journal-title":"Int Immunopharmacol"},{"key":"ref=13","volume":"6","author":"Toljan K.","year":"2018","unstructured":"Toljan K, Vrooman B. Low-Dose Naltrexone (LDN)-review of therapeutic utilization.","journal-title":"Med Sci (Basel)"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/phar.2086","volume":"38","author":"Patten D.K.","year":"2018","unstructured":"Patten DK, Schultz BG, Berlau DJ. The safety and Efficacy of Low-dose Naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn\u2019s Disease, and other chronic pain disorders.","journal-title":"Pharmacotherapy"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/JCP.0000000000000373","volume":"35","author":"Turel A.P.","year":"2015","unstructured":"Turel AP, Oh KH, Zagon IS, McLaughlin PJ. Low dose Naltrexone for treatment of multiple sclerosis: A retrospective chart review of safety and tolerability.","journal-title":"J Clin Psychopharmacol"},{"key":"ref=16","volume":"4","author":"Parker C.E.","year":"2018","unstructured":"Parker CE, Nguyen TM, Segal D, MacDonald JK, Chande N. Low dose naltrexone for induction of remission in Crohn\u2019s disease.","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2174\/1573397113666170321120329","volume":"14","author":"Metyas S.","year":"2018","unstructured":"Metyas S, Chen CL, Yeter K, Solyman J, Arkfeld DG. Low dose Naltrexone in the treatment of fibromyalgia.","journal-title":"Curr Rheumatol Rev"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/pds.4110","volume":"26","author":"Raknes G.","year":"2017","unstructured":"Raknes G, Smabrekke L. A sudden and unprecedented increase in low dose naltrexone (LDN) prescribing in Norway. Patient and prescriber characteristics, and dispense patterns. A drug utilization cohort study.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.jisp.2017.10.012","volume":"19","author":"Atanaskova Mesinkovska N.","year":"2018","unstructured":"Atanaskova Mesinkovska N. Emerging unconventional therapies for","journal-title":"J Investig Dermatol Symp Proc"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1111\/bph.13750","volume":"175","author":"Plein L.M.","year":"2018","unstructured":"Plein LM, Rittner HL. Opioids and the immune system - friend or foe.","journal-title":"Br J Pharmacol"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/exd.13021","volume":"25","author":"Bigliardi P.L.","year":"2016","unstructured":"Bigliardi PL, Dancik Y, Neumann C, Bigliardi-Qi M. Opioids and skin homeostasis, regeneration and ageing - What\u2019s the evidence?","journal-title":"Exp Dermatol"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1177\/1535370217724791","volume":"242","author":"Ludwig M.D.","year":"2017","unstructured":"Ludwig MD, Zagon IS, McLaughlin PJ. Featured article: Serum [Met(5)]-enkephalin levels are reduced in multiple sclerosis and restored by low-dose naltrexone.","journal-title":"Exp Biol Med (Maywood)"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.psym.2011.11.006","volume":"53","author":"Ramanathan S.","year":"2012","unstructured":"Ramanathan S, Panksepp J, Johnson B. Is fibromyalgia an endocrine\/endorphin deficit disorder? Is low dose naltrexone a new treatment option?","journal-title":"Psychosomatics"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.mehy.2008.06.048","volume":"72","author":"Brown N.","year":"2009","unstructured":"Brown N, Panksepp J. Low-dose naltrexone for disease prevention and quality of life.","journal-title":"Med Hypotheses"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"303","DOI":"10.4103\/0970-9185.117045","volume":"29","author":"Kumar K.","year":"2013","unstructured":"Kumar K, Singh SI. Neuraxial opioid-induced pruritus: An update.","journal-title":"J Anaesthesiol Clin Pharmacol"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jaad.2009.08.052","volume":"63","author":"Phan N.Q.","year":"2010","unstructured":"Phan NQ, Bernhard JD, Luger TA, Stander S. Antipruritic treatment with systemic mu-opioid receptor antagonists: a review.","journal-title":"J Am Acad Dermatol"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/0024-3205(93)90581-M","volume":"53","author":"Barke K.E.","year":"1993","unstructured":"Barke KE, Hough LB. Opiates, mast cells and histamine release.","journal-title":"Life Sci"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.drugalcdep.2009.10.011","volume":"108","author":"Trigo J.M.","year":"2010","unstructured":"Trigo JM, Martin-Garcia E, Berrendero F, Robledo P, Maldonado R. The endogenous opioid system: a common substrate in drug addiction.","journal-title":"Drug Alcohol Depend"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1152\/physrev.00005.2009","volume":"89","author":"Le Merrer J.","year":"2009","unstructured":"Le Merrer J, Becker JA, Befort K, Kieffer BL. Reward processing by the opioid system in the brain.","journal-title":"Physiol Rev"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.neubiorev.2010.02.001","volume":"35","author":"Ikemoto S.","year":"2010","unstructured":"Ikemoto S. Brain reward circuitry beyond the mesolimbic dopamine system: a neurobiological theory.","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1089\/wound.2016.0725","volume":"6","author":"McLaughlin P.J.","year":"2017","unstructured":"McLaughlin PJ, Cain JD, Titunick MB, Sassani JW, Zagon IS. Topical Naltrexone is a safe and effective alternative to standard treatment of diabetic wounds.","journal-title":"Adv Wound Care (New Rochelle)"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1001\/jamadermatol.2017.2446","volume":"153","author":"Albers L.N.","year":"2017","unstructured":"Albers LN, Arbiser JL, Feldman RJ. Treatment of hailey-hailey disease with Low-dose Naltrexone.","journal-title":"JAMA Dermatol"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/jid.2014.370","volume":"135","author":"Neumann C.","year":"2015","unstructured":"Neumann C, Bigliardi-Qi M, Widmann C, Bigliardi PL. The delta-opioid receptor affects epidermal homeostasis ERK-dependent inhibition of transcription factor POU2F3.","journal-title":"J Invest Dermatol"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/bph.12687","volume":"172","author":"Bigliardi P.L.","year":"2015","unstructured":"Bigliardi PL, Neumann C, Teo YL, Pant A, Bigliardi-Qi M. Activation of the delta-opioid receptor promotes cutaneous wound healing by affecting keratinocyte intercellular adhesion and migration.","journal-title":"Br J Pharmacol"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10067-014-2517-2","volume":"33","author":"Younger J.","year":"2014","unstructured":"Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain.","journal-title":"Clin Rheumatol"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3389\/fimmu.2017.00809","volume":"8","author":"Cant R.","year":"2017","unstructured":"Cant R, Dalgleish AG, Allen RL. Naltrexone inhibits IL-6 and TNFalpha production in human immune cell subsets following stimulation with ligands for intracellular toll-like Receptors.","journal-title":"Front Immunol"},{"key":"ref=37","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines5020016","volume":"5","author":"Parkitny L.","year":"2017","unstructured":"Parkitny L, Younger J. Reduced pro-inflammatory cytokines after eight weeks of Low-Dose Naltrexone for fibromyalgia.","journal-title":"Biomedicines"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1258\/ebm.2011.011121","volume":"236","author":"Donahue R.N.","year":"2011","unstructured":"Donahue RN, McLaughlin PJ, Zagon IS. Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model.","journal-title":"Exp Biol Med (Maywood)"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1091\/mbc.e08-07-0681","volume":"20","author":"Cheng F.","year":"2009","unstructured":"Cheng F, McLaughlin PJ, Verderame MF, Zagon IS. The OGF-OGFr axis utilizes the p16INK4a and p21WAF1\/CIP1 pathways to restrict normal cell proliferation.","journal-title":"Mol Biol Cell"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.imbio.2010.06.001","volume":"216","author":"Zagon I.S.","year":"2011","unstructured":"Zagon IS, Donahue RN, Bonneau RH, McLaughlin PJ. B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases.","journal-title":"Immunobiology"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.imbio.2010.09.014","volume":"216","author":"Zagon I.S.","year":"2011","unstructured":"Zagon IS, Donahue RN, Bonneau RH, McLaughlin PJ. T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases.","journal-title":"Immunobiol"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12865-015-0093-0","volume":"16","author":"McLaughlin P.J.","year":"2015","unstructured":"McLaughlin PJ, McHugh DP, Magister MJ, Zagon IS. Endogenous opioid inhibition of proliferation of T and B cell subpopulations in response to immunization for experimental autoimmune encephalomyelitis.","journal-title":"BMC Immunol"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.intimp.2018.03.002","volume":"59","author":"Vijay K.","year":"2018","unstructured":"Vijay K. Toll-like receptors in immunity and inflammatory diseases: Past, present, and future.","journal-title":"Int Immunopharmacol"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.autrev.2018.10.005","volume":"18","author":"Toubi E.","year":"2019","unstructured":"Toubi E, Vadasz Z. Innate immune-responses and their role in driving autoimmunity.","journal-title":"Autoimmun Rev"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1460-9568.2008.06321.x","volume":"28","author":"Hutchinson M.R.","year":"2008","unstructured":"Hutchinson MR, Zhang Y, Brown K. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4).","journal-title":"Eur J Neurosci"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1007\/s00018-017-2544-7","volume":"74","author":"Deng H.","year":"2017","unstructured":"Deng H, Xiao H. The role of the ATP2C1 gene in Hailey-Hailey disease.","journal-title":"Cell Mol Life Sci"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jaad.2016.08.039","volume":"76","author":"Farahnik B.","year":"2017","unstructured":"Farahnik B, Blattner CM, Mortazie MB. Interventional treatments for Hailey-Hailey disease.","journal-title":"J Am Acad Dermatol"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1001\/jamadermatol.2017.2445","volume":"153","author":"Ibrahim O.","year":"2017","unstructured":"Ibrahim O, Hogan SR, Vij A, Fernandez AP. Low-Dose Naltrexone treatment of familial benign pemphigus (Hailey-Hailey Disease).","journal-title":"JAMA Dermatol"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1111\/bjd.16045","volume":"178","author":"Campbell V.","year":"2018","unstructured":"Campbell V, McGrath C, Corry A. Low-dose naltrexone: a novel treatment for Hailey-Hailey disease.","journal-title":"Br J Dermatol"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jdcr.2018.07.002","volume":"4","author":"Kollman N.","year":"2018","unstructured":"Kollman N, Bass J. Generalized familial benign chronic pemphigus (Hailey-Hailey disease) treated successfully with low-dose naltrexone.","journal-title":"JAAD Case Rep"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1001\/jamadermatol.2017.5463","volume":"154","author":"Cao S.","year":"2018","unstructured":"Cao S, Lilly E, Chen ST. Variable response to Naltrexone in patients with Hailey-Hailey Disease.","journal-title":"JAMA Dermatol"},{"key":"ref=52","author":"Tran T.","year":"2018","unstructured":"Tran T, Chen A, Worswick S. Successful treatment of dermatomyositis with low-dose naltrexone.","journal-title":"Dermatol Ther"},{"key":"ref=53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111490","volume":"9","author":"Cappelletti C.","year":"2014","unstructured":"Cappelletti C, Galbardi B, Kapetis D. Autophagy, inflammation and innate immunity in inflammatory myopathies.","journal-title":"PLoS One"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10067-009-1316-7","volume":"29","author":"Kim G.T.","year":"2010","unstructured":"Kim GT, Cho ML, Park YE. Expression of TLR2, TLR4, and TLR9 in dermatomyositis and polymyositis.","journal-title":"Clin Rheumatol"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1093\/rheumatology\/ket275","volume":"52","author":"Razykov I.","year":"2013","unstructured":"Razykov I, Levis B, Hudson M, Baron M, Thombs BD. Canadian Scleroderma research G. Prevalence and clinical correlates of pruritus in patients with systemic sclerosis: an updated analysis of 959 patients.","journal-title":"Rheumatology (Oxford)"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1111\/bjd.14998","volume":"176","author":"Therene C.","year":"2017","unstructured":"Therene C, Brenaut E, Sonbol H. Itch and systemic sclerosis: frequency, clinical characteristics and consequences.","journal-title":"Br J Dermatol"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"735","DOI":"10.2340\/00015555-2980","volume":"98","author":"Gourier G.","year":"2018","unstructured":"Gourier G, Therene C, Mazeas M. Clinical characteristics of pruritus in systemic sclerosis vary according to the autoimmune subtype.","journal-title":"Acta Derm Venereol"},{"key":"ref=58","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/804296","volume":"2011","author":"Frech T.","year":"2011","unstructured":"Frech T, Novak K, Revelo MP. Low-dose naltrexone for pruritus in systemic sclerosis.","journal-title":"Int J Rheumatol"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"G252","DOI":"10.1152\/ajpgi.00184.2016","volume":"311","author":"Lay J.","year":"2016","unstructured":"Lay J, Carbone SE, DiCello JJ. Distribution and trafficking of the mu-opioid receptor in enteric neurons of the guinea pig.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1177\/1535370214543061","volume":"239","author":"Immonen J.A.","year":"2014","unstructured":"Immonen JA, Zagon IS, McLaughlin PJ. Selective blockade of the OGF-OGFr pathway by naltrexone accelerates fibroblast proliferation and wound healing.","journal-title":"Exp Biol Med (Maywood)"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jdcr.2018.06.001","volume":"4","author":"Bridgman A.C.","year":"2018","unstructured":"Bridgman AC, Kirchhof MG. Treatment of psoriasis vulgaris using low-dose naltrexone.","journal-title":"JAAD Case Rep"},{"key":"ref=62","first-page":"270","volume":"22","author":"Muller G.","year":"2018","unstructured":"Muller G, Grieshaber R, Talley JF, Riepl M, Fellows D. Compounded low-dose Naltrexone for the treatment of Guttate Psoriasis: A case report.","journal-title":"Int J Pharm Compd"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1111\/1346-8138.14647","volume":"45","author":"Sikora M.","year":"2018","unstructured":"Sikora M, Chrabaszcz M, Maciejewski C. Intestinal barrier integrity in patients with plaque psoriasis.","journal-title":"J Dermatol"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12967-018-1427-5","volume":"16","author":"Lie M.","year":"2018","unstructured":"Lie M, van der Giessen J, Fuhler GM. Low dose Naltrexone for induction of remission in inflammatory bowel disease patients.","journal-title":"J Transl Med"},{"key":"ref=65","first-page":"1140","volume":"16","author":"Strazzulla L.C.","year":"2017","unstructured":"Strazzulla LC, Avila L, Lo Sicco K, Shapiro J. Novel treatment using low-dose Naltrexone for Lichen Planopilaris.","journal-title":"J Drugs Dermatol"},{"key":"ref=66","volume":"2013","author":"Welz-Kubiak K.","year":"2013","unstructured":"Welz-Kubiak K, Reich A. Mediators of pruritus in lichen planus.","journal-title":"Autoimmune Dis"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/00004714-199512000-00012","volume":"15","author":"Carrion V.G.","year":"1995","unstructured":"Carrion VG. Naltrexone for the treatment of trichotillomania: a case report.","journal-title":"J Clin Psychopharmacol"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jamda.2014.01.007","volume":"15","author":"Oravecz R.","year":"2014","unstructured":"Oravecz R, Stuhec M. Trichotillomania successfully treated with risperidone and naltrexone: a geriatric case report.","journal-title":"J Am Med Dir Assoc"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/JCP.0000000000000037","volume":"34","author":"Grant J.E.","year":"2014","unstructured":"Grant JE, Odlaug BL, Schreiber LR, Kim SW. The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study.","journal-title":"J Clin Psychopharmacol"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1089\/cap.2006.0111","volume":"18","author":"De Sousa A.","year":"2008","unstructured":"De Sousa A. An open-label pilot study of naltrexone in childhood-onset trichotillomania.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.det.2018.02.008","volume":"36","author":"Dull M.M.","year":"2018","unstructured":"Dull MM, Kremer AE. Management of chronic hepatic itch.","journal-title":"Dermatol Clin"},{"key":"ref=72","first-page":"1022","volume":"91","author":"Carson K.L.","year":"1996","unstructured":"Carson KL, Tran TT, Cotton P, Sharara AI, Hunt CM. Pilot study of the use of naltrexone to treat the severe pruritus of cholestatic liver disease.","journal-title":"Am J Gastroenterol"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/gast.1997.v113.pm9322521","volume":"113","author":"Wolfhagen F.H.","year":"1997","unstructured":"Wolfhagen FH, Sternieri E, Hop WC. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study.","journal-title":"Gastroenterol"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0168-8278(02)00318-5","volume":"37","author":"Terg R.","year":"2002","unstructured":"Terg R, Coronel E, Sorda J, Munoz AE, Findor J. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study.","journal-title":"J Hepatol"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3748\/wjg.v12.i7.1125","volume":"12","author":"Mansour-Ghanaei F.","year":"2006","unstructured":"Mansour-Ghanaei F, Taheri A, Froutan H. Effect of oral naltrexone on pruritus in cholestatic patients.","journal-title":"World J Gastroenterol"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.det.2018.02.011","volume":"36","author":"Serrano L.","year":"2018","unstructured":"Serrano L, Martinez-Escala ME, Zhou XA, Guitart J. Pruritus in cutaneous T-Cell lymphoma and its management.","journal-title":"Dermatol Clin"},{"key":"ref=77","doi-asserted-by":"crossref","DOI":"10.1177\/2054358116675345","volume":"3","author":"Jaiswal D.","year":"2016","unstructured":"Jaiswal D, Uzans D, Hayden J, Kiberd BA, Tennankore KK. Targeting the opioid pathway for uremic pruritus: A systematic review and meta-analysis.","journal-title":"Can J Kidney Health Dis"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1159\/000077841","volume":"208","author":"Legroux-Crespel E.","year":"2004","unstructured":"Legroux-Crespel E, Cledes J, Misery L. A comparative study on the effects of naltrexone and loratadine on uremic pruritus.","journal-title":"Dermatology"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/S0140-6736(96)04176-1","volume":"348","author":"Peer G.","year":"1996","unstructured":"Peer G, Kivity S, Agami O. Randomised crossover trial of naltrexone in uraemic pruritus.","journal-title":"Lancet"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1681\/ASN.V113514","volume":"11","author":"Pauli-Magnus C.","year":"2000","unstructured":"Pauli-Magnus C, Mikus G, Alscher DM. Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study.","journal-title":"J Am Soc Nephrol"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/j.1468-3083.2009.03129.x","volume":"23","author":"Malekzad F.","year":"2009","unstructured":"Malekzad F, Arbabi M, Mohtasham N. Efficacy of oral naltrexone on pruritus in atopic eczema: a double-blind, placebo-controlled study.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=82","doi-asserted-by":"crossref","first-page":"159","DOI":"10.5021\/ad.2016.28.2.159","volume":"28","author":"Lee J.","year":"2016","unstructured":"Lee J, Shin JU, Noh S, Park CO, Lee KH. Clinical efficacy and safety of Naltrexone combination therapy in older patients with severepruritus.","journal-title":"Ann Dermatol"},{"key":"ref=83","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12916-018-1242-0","volume":"17","author":"Bolton M.","year":"2019","unstructured":"Bolton M, Hodkinson A, Boda S. Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis.","journal-title":"BMC Med"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/170794","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T23:55:00Z","timestamp":1663113300000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/170794\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,12]]},"references-count":83,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,7,12]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389450120666190318121122","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7,12]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-12-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}